Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases.
It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline.
The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.16 Increased by +11.11% | -0.07 Decreased by -128.57% |
| Feb 28, 24 | -0.11 Increased by +42.11% | -0.06 Decreased by -83.33% |
| Nov 8, 23 | -0.07 Increased by +41.67% | -0.08 Increased by +12.50% |
| Aug 8, 23 | -0.15 Increased by +28.57% | -0.12 Decreased by -25.00% |
| May 10, 23 | -0.18 Increased by +40.00% | -0.15 Decreased by -20.00% |
| Mar 1, 23 | -0.19 Increased by +34.48% | -0.13 Decreased by -46.15% |
| Nov 7, 22 | -0.12 Increased by +36.84% | -0.19 Increased by +36.84% |
| Aug 4, 22 | -0.21 Decreased by -10.53% | -0.22 Increased by +4.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 103.50 M Increased by +26.70% | -21.58 M Increased by +35.18% | Decreased by -20.85% Increased by +48.84% |
| Jun 30, 23 | 94.50 M Increased by +17.06% | -43.23 M Increased by +30.45% | Decreased by -45.75% Increased by +40.58% |
| Mar 31, 23 | 86.27 M Increased by +9.60% | -52.93 M Increased by +37.92% | Decreased by -61.36% Increased by +43.35% |
| Dec 31, 22 | 88.10 M Increased by +7.23% | -55.87 M Increased by +32.92% | Decreased by -63.41% Increased by +37.44% |
| Sep 30, 22 | 81.69 M Increased by +2.70% | -33.29 M Increased by +33.82% | Decreased by -40.75% Increased by +35.56% |
| Jun 30, 22 | 80.73 M Increased by +4.29% | -62.16 M Decreased by -21.34% | Decreased by -76.99% Decreased by -16.35% |
| Mar 31, 22 | 78.72 M Increased by +18.54% | -85.26 M Decreased by -29.84% | Decreased by -108.31% Decreased by -9.53% |
| Dec 31, 21 | 82.15 M Increased by +16.41% | -83.28 M Decreased by -16.63% | Decreased by -101.37% Decreased by -0.19% |